ROCKVILLE, Md., Nov. 06, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and innovative
RNS Number : 0789S MaxCyte, Inc. 01 November 2023 MaxCyte, Inc. (" MaxCyte " or the "Company") Total Voting Rights ROCKVILLE, Maryland - 1 November 2023 : MaxCyte Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell - engineering company focused on providing enabling platform
RNS Number : 7367O MaxCyte, Inc. 05 October 2023 MaxCyte Announces Preliminary Third Quarter 2023 Revenue and Updates Full Year 2023 Revenue Guidance ROCKVILLE, MD , October 5, 2023 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling
ROCKVILLE, Md., Oct. 04, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and innovative
RNS Number : 4224O MaxCyte, Inc. 02 October 2023 MaxCyte, Inc. (" MaxCyte " or the "Company") Total Voting Rights ROCKVILLE, Maryland - 2 October 2023: MaxCyte Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell - engineering company focused on providing enabling platform
RNS Number : 3508M MaxCyte, Inc. 13 September 2023 TR-1: Notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which
RNS Number : 1986M MaxCyte, Inc. 12 September 2023 TR-1: N otification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which
ROCKVILLE, Md., Sept. 06, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc. , (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support
RNS Number : 5613L MaxCyte, Inc. 06 September 2023 MaxCyte Appoints Ali Soleymannezhad as Executive Vice President of Bioprocessing ROCKVILLE, MD , September 6, 2023 - MaxCyte, Inc. , (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling
RNS Number : 4644L MaxCyte, Inc. 05 September 2023 TR-1: N otification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which
